Insights
Insights From Our Experts
Articles
Matching-Adjusted Indirect Comparison (MAIC): An Established Methodology for Comparing Treatment Efficacies Across Trials
In the realm of comparative effectiveness research (CER), decision-makers often face challenges when attempting to compare treatment efficacies due to limited availability of comparative data, especially for new therapies. This white paper introduces the Matching-Adjusted Indirect…
Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment
These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes…
From Limitations to Expansions: How Prioritizing Patients’ Speed to Therapy Drives Therapy Adoption
Navigating the launch of a new product is a complex and ever-evolving journey for manufacturers. With hundreds of millions of dollars and an abundance of other significant resources invested in a product’s pre-launch commercialization efforts, meeting…
Case Study: Primary Research Meets Data-Driven Sources and Technology to Form Powerful Market Access Solutions
The case for primary market research, Real-World Data (RWD), and deep healthcare experience combined to deliver targeted market access strategies. As diseases become more complex and market access becomes more restrictive, with multiple sources of market…
2023 Outlook Of China Healthcare Industry: Remaining Pragmatic While Moving Up The Value Chain
As we enter 2023, China surprised the world with a swift and decisive shift in COVID policy, demonstrating the country’s ability to be flexible and pragmatic in its decision-making. In contrast to Russia’s persistent adherence to…
A Framework for Branded Pharma Companion Apps Is Coming Soon
The FDA just announced plans to release a draft guidance on prescription drug-use-related software later this year. What should the pharma industry expect? The past three years have seen a significant increase in the acceptance and…
The Necessity of Mapping the Tumor Journey for Oncology Marketers
EVERSANA INTOUCH has been pioneering a Tumor Journey that considers the complex, multi-factorial decision making that permeates every stage of oncologic patient care. Oncology Marketing has been slow in evolving to consider the complexities of diagnosis,…
European Commission’s Long-awaited Pharma Legislation Review Gets Mixed Reception
NAVLIN Brief The European Commission has finally released its proposal to revise the European Union’s pharmaceutical legislation. The document includes proposals for a new Directive and a new Regulation, which revise and replace the existing pharmaceutical…
Left-Right-Left: The Latest in Pharma-Payer Ping Pong
Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have…
Your Guide to Developing a Best-in-Class Specialty Pharmacy Network Strategy
Why Develop a Specialty Pharmacy Network Strategy? Specialty pharmaceuticals often require high-touch, labor-intensive services to expedite patient access and improve therapy adherence. Additionally, patients requiring specialty therapies are often medically complex and challenging to manage. These…